Home » Newsletters » BioWorld Science

BioWorld Science

July 11, 2008

View Archived Issues

Novel acronycine derivatives with in vivo antitumor activity

Spider toxin shows potential to alleviate mechanical pain

Promising activity of GTI-2040 in combination with AraC in acute myeloid leukemia

New treatments for obesity disclosed in recent patent literature

Novel anti-HIV agents patented by Roche and Bayer

Recent Aska patent describes novel agents for urinary disorders

CYT003-QbG10 monotherapy was safe and effective in phase II allergic disease studiey

Icagen completes phase I multiple ascending dose trial of senicapoc

OrthoLogic initiates dosing in AZX-100 phase I dermal/hypertrophic scarring trial

Sosei completes phase III NorLevo trial in emergency contraception

ValiRx acquires global rights to VAL-201 for prostate cancer

Ortho Biotech returns Japanese rights for Yondelis to PharmaMar

IND submitted on behalf of Generex for immunotherapy vaccine trial

Genmab completes recruitment in phase II ofatumumab study in CLL

Novartis plans to acquire remaining shares in Speedel Holding

Calistoga initiates phase I clinical trial of PI3K delta inhibitor CAL-101

VIA Pharmaceuticals completes patient visits in phase II CEA trial of VIA-2291

CV Therapeutics receives E.U. marketing authorization for ranolazine

Compugen has reported positive results from an in vivo study of CGEN-25007

FDA approves NeuroSearch's IND application for ACR-16 in Huntington's disease

Ardea moves RDEA-806 into phase IIa proof-of-concept study for gout

Access signs merger agreement to Acquire MacroChem

Preemptive treatment reduces skin toxicities in patients treated with panitumumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...